Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice

Completed

Conditions studied: Multiple Sclerosis

In brief

This was a retrospective cohort study using the electronic medical record (EMR) database from Cleveland Clinic. The data was analyzed at start of ofatumumab (OMB) therapy (baseline, defined as 6 months prior to OMB initiation) and at 6 or 12 months following initiation of OMB.

Key facts

Study ID

NCT06737419

Run by

Novartis Pharmaceuticals

People needed

175

Starts

2021-06-09

Expected to finish

2024-02-05

Last updated by the study team

2024-12-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who initiated OMB commercially from the time of disease modifying therapy (DMT) approval (August 2020), and
• Aged 18 years or older at index date, and
• Patients who met 2017 McDonald Criteria for clinically definite multiple sclerosis (MS), or
• Patients diagnosed with clinically isolated syndrome (CIS) by Cleveland Clinic MS specialist.
• Exclusion criteria: Those who were participating in OMB clinical trials (e.g., ARTIOS, OLIKOS)

Where it is running

• Novartis — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.